STERIS (STE) has drawn fresh attention after reporting first quarter results with higher sales and net income, reaffirming its fiscal 2027 revenue outlook and committing US$600 million to a new North Carolina Center of Excellence.

Over the past month STERIS has seen a 9.01% share price return and a 9.55% share price return over the last 90 days, while the year to date share price return is down 5.38% and the 1 year total shareholder return is down 3.22%. Taken together, these figures point to improving short term momentum but a more muted longer term outcome so far.

If this mix of earnings growth, dividends and capital investment has your attention, it can be useful to compare STERIS with other healthcare-focused opportunities that might benefit from similar trends, including companies in infection control and medical technology, by reviewing the 43 healthcare AI stocks.

STERIS has reported solid quarterly numbers while the share price has only recently begun to move. Is this latest bounce catching up with the business, or is it more about changing sentiment at today’s valuation?

Most Popular Narrative: 9.8% Undervalued

The most followed narrative for STERIS compares its fair value of $262.25 to the last close of $236.60 and concludes the shares trade at a discount that hinges on specific growth and margin assumptions.

Continued expansion of STERIS's consumables and services segments with high recurring revenue and margin visibility positions the company to benefit from increasing healthcare expenditures and adoption of best-practice infection control standards, supporting both revenue and margin expansion.

Want to see what sits behind that confidence in recurring revenue and margins? The narrative leans on a specific growth path, firmer profitability and a premium earnings multiple to bridge the gap between $236.60 and $262.25.

Result: Fair Value of $262.25 (UNDERVALUED)

However, STERIS investors still need to watch tariff-related cost pressure and any slowdown in healthcare and bioprocessing demand that could unsettle the current margin narrative.

Another View On STERIS Using Market Ratios

The STERIS fair value narrative leans on future growth and margins, yet today the stock trades on a P/E of 28.7x. That is higher than the US Medical Equipment industry at 26.3x and above a fair ratio of 26.4x, which points to valuation risk if expectations slip even a little. Could this premium simply reflect confidence that the current growth path holds, or is the market stretching too far?

Next Steps

Mixed signals on STERIS so far. If you want to move quickly and build your own view from the ground up, start by weighing the 2 key rewards and 1 important warning sign.

Looking for more STERIS style investment ideas?

If STERIS has sharpened your focus on quality opportunities, do not stop here. The right screen can quickly surface stocks that better fit your goals.

• Zero in on potential mispricings by reviewing the 49 high quality undervalued stocks that pair solid fundamentals with compelling price tags.
• Prioritise resilience and sleep easier at night by checking companies in the 85 resilient stocks with low risk scores that score well on stability.
• Stay ahead of the crowd by scanning the screener containing 20 high quality undiscovered gems before these opportunities attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.